HIV RNA Screening Reduces Integrase Strand Transfer Inhibitor Resistance Risk in Persons Receiving Long-Acting Cabotegravir for HIV PreventionSusan H. Eshleman, Richard Clark, Marty St. Clair et al.|The Journal of Infectious Diseases|2022Cited by 37
Features of HIV Infection in the Context of Long-Acting Cabotegravir Preexposure ProphylaxisRaphael J. Landovitz, Susan H. Eshleman, Sinéad Delany‐Moretlwe et al.|New England Journal of Medicine|2024Cited by 37
Extended Analysis of HIV Infection in Cisgender Men and Transgender Women Who Have Sex with Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083Mark A. Marzinke, Susan H. Eshleman, Jessica M. Fogel et al.|Antimicrobial Agents and Chemotherapy|2023Cited by 30
Features of HIV Infection in the Context of Long-Acting Cabotegravir Preexposure ProphylaxisDeborah Donnell, Jessica M. Fogel, Paul A. Richardson et al.|UNC Libraries|2025Cited by 0
Sustained HIV Suppression With Co-formulated Tenofovir Disoproxil Fumarate/Lamivudine/Dolutegravir in a Person With Transmitted Dolutegravir Resistance and Pretreatment Resistance to Lamivudine: a Case Report From HPTN 083Hannah P. Moore, Susan H. Eshleman, Jessica M. Fogel et al.|Open Forum Infectious Diseases|2025Cited by 0